hotspot -WSS

hotspot

author：leisure time 2025-09-30 22:05:22 - browse：92589

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Scrutiny of post

leisure time

WSS

Bird flu surveillance in wastewater gets boost from consortium

Reports of telehealth's death have been greatly exaggerated

What don’t we know about an Alzheimer’s drug side effect?

Scrutiny of post

ASCO eve: Let’s set the table for this year's meeting

Diagnostic tests are hitting their mathematical limits

focus

hotspot

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

Flagship Pioneering launches a new biotech in two countries

Hepatitis C has a cure — but many Americans still lack access to it

Diagnostic tests are hitting their mathematical limits

Walensky prepares to leave CDC — and Congress — behind

30 years of 'Listening to Prozac'

BioMarin wins approval for gene therapy to treat hemophilia A

Cigna, Humana reportedly in talks to merge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

What to do when lifesaving products contribute to climate change

Cue Health, Covid

At flashy new research hub, AstraZeneca lays out ambitious growth goals

H5N1 virus can be tracked in retail milk, scientists say

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Cue Health, Covid

knowledge

leisure time

Wikipedia

explore